Phase I Study Of Safety And Pharmacokinetics (Pk) Of Gdc-0917, An Antagonist Of Inhibitor Of Apoptosis (Iap) Proteins In Patients (Pts) With Refractory Solid Tumors Or Lymphoma.

Anthony W. Tolcher,Kyriakos P. Papadopoulos,Amita Patnaik,Wayne J. Fairbrother,Harvey Wong,Nageshwar R. Budha,Walter C. Darbonne,Franklin V. Peale,Michael J. Mamounas,Stephanie Royer-Joo,Ron Yu,Chia C. Portera,Johanna C. Bendell,Howard A. Burris,Jeffrey R. Infante

JOURNAL OF CLINICAL ONCOLOGY（2013）

引用 13|浏览2

暂无评分

摘要

2503 Background: GDCE0917 is a small molecule that triggers tumor cell apoptosis by selectively antagonizing IAP proteins. Preclinical studies demonstrated antitumor efficacy of GDC-0917 alone or i...

查看译文

关键词

Inhibitor of apoptosis,Lymphoma,Pharmacokinetics,Antagonist,Small molecule,Pharmacology,Refractory,Medicine,In patient,Phase i study

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要